March 6, 2018 / 12:36 PM / 8 months ago

BRIEF-Bioverativ Announces First Patient Dosed In Phase 3 Study Of BIVV009 For Cold Agglutinin Disease Treatment

March 6 (Reuters) - Bioverativ Inc:

* BIOVERATIV ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 STUDY OF BIVV009 FOR TREATMENT OF COLD AGGLUTININ DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below